CN111281971A - 一种具有降低血粘度的药物组合物 - Google Patents
一种具有降低血粘度的药物组合物 Download PDFInfo
- Publication number
- CN111281971A CN111281971A CN202010176270.3A CN202010176270A CN111281971A CN 111281971 A CN111281971 A CN 111281971A CN 202010176270 A CN202010176270 A CN 202010176270A CN 111281971 A CN111281971 A CN 111281971A
- Authority
- CN
- China
- Prior art keywords
- kernel
- kinase
- parts
- granules
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008280 blood Substances 0.000 title claims abstract description 25
- 210000004369 blood Anatomy 0.000 title claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 41
- 108091000080 Phosphotransferase Proteins 0.000 claims abstract description 34
- 102000020233 phosphotransferase Human genes 0.000 claims abstract description 34
- 239000000284 extract Substances 0.000 claims abstract description 26
- 238000002156 mixing Methods 0.000 claims abstract description 17
- 239000002775 capsule Substances 0.000 claims abstract description 15
- 239000008187 granular material Substances 0.000 claims abstract description 15
- 229940026314 red yeast rice Drugs 0.000 claims abstract description 12
- 102000001253 Protein Kinase Human genes 0.000 claims abstract description 10
- 108060006633 protein kinase Proteins 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims description 17
- 239000000706 filtrate Substances 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 239000002002 slurry Substances 0.000 claims description 10
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 8
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 8
- 244000020518 Carthamus tinctorius Species 0.000 claims description 7
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 7
- 240000005373 Panax quinquefolius Species 0.000 claims description 7
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 7
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 7
- 244000144730 Amygdalus persica Species 0.000 claims description 6
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 6
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 6
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 6
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 6
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 6
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 6
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 6
- 240000000171 Crataegus monogyna Species 0.000 claims description 6
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 6
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 6
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 6
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 244000063299 Bacillus subtilis Species 0.000 claims description 5
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 5
- 241000305491 Gastrodia elata Species 0.000 claims description 5
- 244000131316 Panax pseudoginseng Species 0.000 claims description 5
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 5
- 241001080798 Polygala tenuifolia Species 0.000 claims description 5
- 244000042430 Rhodiola rosea Species 0.000 claims description 5
- 235000003713 Rhodiola rosea Nutrition 0.000 claims description 5
- 241000921449 Rhodobryum roseum Species 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 238000000855 fermentation Methods 0.000 claims description 5
- 230000004151 fermentation Effects 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 241000180649 Panax notoginseng Species 0.000 claims description 4
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 4
- 235000008326 Trichosanthes anguina Nutrition 0.000 claims description 4
- 244000078912 Trichosanthes cucumerina Species 0.000 claims description 4
- 238000007796 conventional method Methods 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 241000037488 Coccoloba pubescens Species 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 241000628997 Flos Species 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 238000007605 air drying Methods 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 238000010025 steaming Methods 0.000 claims description 2
- 102000007999 Nuclear Proteins Human genes 0.000 claims 1
- 108010089610 Nuclear Proteins Proteins 0.000 claims 1
- 241000304195 Salvia miltiorrhiza Species 0.000 claims 1
- 239000012676 herbal extract Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 22
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 8
- 238000011084 recovery Methods 0.000 abstract description 5
- 240000001548 Camellia japonica Species 0.000 abstract description 3
- 235000018597 common camellia Nutrition 0.000 abstract description 3
- 238000012795 verification Methods 0.000 abstract description 3
- 238000007405 data analysis Methods 0.000 abstract description 2
- 230000036541 health Effects 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 230000017531 blood circulation Effects 0.000 description 5
- 244000132619 red sage Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940126680 traditional chinese medicines Drugs 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 239000010282 Emodin Substances 0.000 description 3
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 3
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 3
- 102100021010 Nucleolin Human genes 0.000 description 3
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 3
- 241001165494 Rhodiola Species 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 108010044762 nucleolin Proteins 0.000 description 3
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 241000208966 Polygala Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 2
- 235000013882 gravy Nutrition 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- BDHQMRXFDYJGII-UEBIAWITSA-N 24-methylenecycloartanol Chemical compound CC(C)([C@@H](O)CC1)[C@H]2[C@@]31C[C@@]13CC[C@]3(C)[C@@H]([C@H](C)CCC(=C)C(C)C)CC[C@@]3(C)[C@@H]1CC2 BDHQMRXFDYJGII-UEBIAWITSA-N 0.000 description 1
- KKSCKZFKHNHGEO-UHFFFAOYSA-N 24-methylenecycloartanol Natural products CC(CCC(=C)C(C)(C)O)C1CCC2C3CCC4C(C)(C)C(O)CCC45CC35CCC12C KKSCKZFKHNHGEO-UHFFFAOYSA-N 0.000 description 1
- BJZVHTWNCLKZGN-SPQNPFHSSA-N 24-methylidenecycloartanol Natural products CC(C)C(=C)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C(C)(C)[C@@H](O)CC[C@@]45C[C@@]35CC[C@]12C BJZVHTWNCLKZGN-SPQNPFHSSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- CBOKHFLBNZMMAA-UHFFFAOYSA-N Emodin anthrone Natural products OC1=CC(O)=CC2=CC3=CC(C)=CC(O)=C3C(O)=C21 CBOKHFLBNZMMAA-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 241000921453 Rhodobryum Species 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 241000218989 Trichosanthes Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- LAJSXCAVRQXZIO-UHFFFAOYSA-N emodin anthrone Chemical compound C1=C(O)C=C2CC3=CC(C)=CC(O)=C3C(=O)C2=C1O LAJSXCAVRQXZIO-UHFFFAOYSA-N 0.000 description 1
- -1 emodin glucoside Chemical class 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 229940057059 monascus purpureus Drugs 0.000 description 1
- YUPVNRBAQHISRY-UHFFFAOYSA-N multiflorin Natural products COC(=O)C1=COC2OCC3OC(=O)CC1C23 YUPVNRBAQHISRY-UHFFFAOYSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/10—Bryophyta (mosses)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Immunology (AREA)
Abstract
本发明公开的是一种具有降低血粘度的药物组合物，由子仁激酶、红曲和中药提取物制备：取子仁激酶和红曲混合均匀，再加入中药提取物混合均匀，先制备成颗料剂，再将颗料剂压片，或将颗粒剂分装入胶囊，每片或每粒胶囊含子仁激酶的量是0.126‑0.128克。本发明具有治疗心血管疾病的作用，尤其是对于降低高粘血症、消除动脉回声斑的调整，效果确切，经广西壮族自治区陆川县茶花山医院进行了临床验证，对高粘血症经过两个疗程的服用观察，保健防治作用有效率100%，恢复正常率在80%左右，以上数据分析统计P≤0.01，有医学临床价值。服用子仁激酶片3个疗程，回声斑全部消失，说明坚持较长时间服用子仁激酶片，具有消除动脉回声斑作用，具有临床意义。
Description
技术领域
本发明涉及的是一种具有降低血粘度的药物组合物，属于中药制备技术领域。
背景技术
众所周知，人体的许多涉及心血管病和脑血管病，引起的病因或多或少都与血粘度有关，血粘度高容易诱发血小板聚集，直接或间接带来一系列疾病，如高血压病、冠心病、血管栓塞、中风等。因此，治疗这类涉及心脑血管疾病采取的主要措施之一就是降低血粘度。可见，维持正常的血粘度对人体而言是多么的重要。而随着生活节奏的加快，饮食习惯的改变，环境的影响，高粘血症成了常见病和多发病，治疗高粘血症较为有效的药物就是阿司匹林，需要长期服用，长期服用的药物带来的不良反应对人体也是一种侵害，其次是具有活血化瘀作用的中药，目前，有这方面作用的中药虽然具有一定的效果，但显效慢，也需要长期服用，适用于调理。中药是一个巨大的宝库，里面蕴藏着丰富的资源，通过科学合理的筛选，是能够筛选出具有更好效果的治疗药物的，但中药的不足是显效慢，效果不明显，需要长期服用才能显效，如何克服这一不足，而又不失中药的不良反应小，用药安全的特点，这就是我们要努力的方向。据报道，蛋白激酶是一类磷酸转移酶，其作用是将ATP的γ磷酸基转移到底物特定的氨基酸残基上，使蛋白质磷酸化。通过蛋白质磷酸化从而调节蛋白质的活性，或者通过蛋白质的逐级磷酸化，使信号逐级放大，引起细胞反应，得蛋白质具有不同的活性。许多具有活血化瘀作用的中药，含有的主要成份是蛋白质，通过对这些含有蛋白质的中药进行微生物发酵，使这些中药中的蛋白质转化为蛋白质激酶，赋予中药新的生物活性，或活性作用更强。从这一原理出发通过科学合理的配伍，并经临床验证，制备出具有迅速、有效和安全地降低血粘度的药物，就是本发明的意义所在。
发明内容
本发明的目的就是提供一种具有降低血粘度的药物组合物，制备出具有迅速、有效和安全地降低血粘度的药物。克服传统的中药治疗高血粘症时作用弱，起效慢，需长期服用的不足。
为实现上述目的，本发明采用了下述技术措施，一种具有降低血粘度的药物组合物，由下述重量份原料制备而成：
配方：
子仁激酶 3-5份 红曲 2-4份 中药提取物 1-2份；
通过下述制备方法将上述原料制备成片剂或胶囊剂：
取子仁激酶和红曲提取物混合均匀，再加入中药提取物混合均匀，根据制备片剂的常规工艺要求加入辅料，先制备成颗料剂，再将颗料剂压片即得到片剂，或将颗粒剂分装入胶囊即得到胶囊剂，所述片剂中每片含子仁激酶的量是0.126-0.128克，所述胶囊剂中每粒含子仁激酶的量是0.126-0.128克。
所述子仁激酶的制备方法：取等量炒决明子和炒桃仁，烘干，粉碎为40-80目细粉，以1:1.2-1.7的重量比用水调成浆状,浸润20-30分钟后，隔水蒸30-40分钟，使蛋白变性得到子仁浆，于35公斤子仁浆中加入30-50毫升枯草芽胞杆菌培养液,搅拌均匀, 在35℃-40℃的条件下发酵18-24小时，期间每4小时搅拌 一次，让子仁浆均匀发酵,取发酵好的子仁浆置于5℃8℃的条件下稳定后熟24-30小时，取出于35℃-40℃以下的温度干燥至含水量为7％以下即得。
所述中药提取物的制备方法：
配方：丹参3-4重量份 山楂2-3重量份 红花1-2重量份
三七1-2重量份 天麻1-2重量份 红景天2-3重量份
远志2-3重量份 瓜蒌壳2-3重量份 回心草2-3重量份 花旗参1-2重量份；
制备方法：取丹参、山楂、红花、红景天、远志、瓜蒌壳和回心草洗净、晾干，加入5-8倍量的水浸泡1小时，加热提取2小时，过滤得滤液备用，残渣按上述方法重复提取1次，收集2次提取的滤液，减压浓缩，浓缩至80℃时检测相对密度为1.12-1.15，得到药物提取液备用；
另取三七、天麻和花旗参，冼净，干燥，粉碎为200目细粉，得到药物细粉备用；
将上述药物细粉加入上述药物提取液中混合均匀，按常规方法加入适量辅料制备成颗粒，干燥，使得每克颗粒剂含生药量为2.5-3克，即得中药提取物。
采取上述措施的本发明，取枯草芽孢杆菌对炒决明子和炒桃仁进行发酵，从而使炒决明子和炒桃仁产生了生物反应，反应产物之一就是子仁激酶，由此而产生了一系列的活性作用。经广西壮族自治区分析测试中心对五批子仁激酶进行检验，活性单位2839U/g-4230U/g，由此提示子仁激酶具有较强的生理活性。产生子仁激酶的两种中药，其中决明子的功效是清肝，明目，利水，通便, 现代研究表明，决明子除含有糖类、蛋白质、脂肪外，还含有人体必需的微量元素铁、锌、锰、铜、镍、钴、钼等。所含大黄素、大黄酸对人体有平喘、利胆、保肝、降压功效，并有一定抗菌、消炎作用。其中大黄素葡萄糖甙、大黄素蒽酮、大黄素甲醚，具有降低血清胆固醇和强心作用。现代临床用决明子治疗高脂血症收效满意。
桃仁含苦杏仁苷、野樱桃苷、2,4-次甲基珂阿尔廷醇、多花蔷薇苷、尿囊素、维生素B1、苦杏仁酶、脂肪油、脂肪酸、蛋白质等另含24-亚甲基环木菠萝烷醇、柠檬甾二烯醇、7-去氢燕麦固醇等成分。
现代研究表明桃仁提取液能明显增加脑血流量，增加犬股动脉的血流量，降低血管阻力，改善血流动力学状况。本发明就是根据决明子和桃仁所含有成份及具有的功效，通过采用枯草芽胞杆菌的发酵，得到的激酶强化了治疗心血管疾病的作用。
本发明所述的中药提取物的配方，是申请人长期实践中总结出来的组方，对心血管疾病的治疗行之有效，其中药物的君、臣、佐、使分工分确，各司其职，君药为丹参、三七、红花，臣药为花旗参、天麻，佐药为山楂、红景天、回心草，使药为瓜蒌壳、远志。将上述药物提取物与子仁激酶配合后，强化了治疗心血管疾病的作用，起到了增效的目的。
本发明所用红曲中，含有洛伐它汀成份，洛伐它汀是已被证明了功效的治疗心血管疾病药物。
将上述子仁激酶、中药提取物和红曲配合制备成中药组合物后，具有治疗心血管疾病的作用，尤其是对于降低高粘血症、消除动脉回声斑的调整，效果确切，经广西壮族自治区陆川县茶花山医院进行了临床验证，结果如下：
于2018年3月-2019年10月对9名志愿者进行高粘血症临床验证，经北海市人民医院和玉林市茶花山医院做了“血液流变学”测试，9人志愿者中有7人在服用子仁激酶前全血粘度：低切、中切、高切均高于正常值，诊断为高粘血症。经每天早、晚两次，饭后服用子仁激酶片18片，连服两个疗程，每个疗程30天，再经原医院复查“血液流变学”测试，将两次测试结果进行前后对比：
低切：（mp.s ）10(1/s)正常值是6.80-9.85，服用子仁激酶片前的数值分别在10.07-14.10之间，7人都是超正常值，服用子仁激酶片后检测，数值分别在9.06-9.86之间，7人服用，全部都有降低，占比100%，其中5人都恢复正常，恢复正常率71.14%。
中切：（mp.s ）60(1/s)正常值是4.51-5.85，服用子仁激酶片前的数值分别在5.78-7.04之间，7人中有6人超正常值，服用子仁激酶片后检测，数值分别在4.61-5.57之间，7人服用，全部都有降低，占比100%，6人都恢复正常，恢复正常率85.7%。
高切：（mp.s ）150(1/s)正常值是3.73-4.60，服用子仁激酶片前的数值分别在4.88-5.57之间，7人都超正常值，服用子仁激酶片后检测，数值分别在3.99-5.15之间，7人服用，全部都有降低，占比100%，其中6人都恢复正常，恢复正常率85.7%。
通过以上7人服用子仁激酶片的统计，院方认为子仁激酶不良反应不明显，安全性较好，对高粘血症经过两个疗程的服用观察，保健防治作用有效率100%，恢复正常率在80%左右，以上数据分析统计
P≤0.01，可信，有医学临床价值。
于2018年3月至2019年11月，对14例志愿者进行了临床观察，服用子仁激酶片前先后在北海市中医院、玉林市第二人民医院、玉林市福绵区人民医院进行了B超检查。其国8例服用前B超检查回声斑在2-25.6mm之间，对这8例回声斑患者，经每天早、晚两次，饭后服用子仁激酶片18-20片，连服2-3个疗程，每个疗程30天，在服用前同一医院进行B超复查，复查结果是8例中有7例回声斑都有缩小，缩小率点人数的87.5%，8例中有一例，回声斑数据没有缩小，但血管壁光洁，血流量增加，说明对清理血管壁，增加血流量具有一定治疗作用。7例回声斑中有缩小，其中一例服用前B超检查，腹主动脉壁上见多个强回声斑光团，其中一个16.1х3.1mm,服用子仁激酶片3个疗程后复查，没有发现回声斑，全部消失，说明随着服用时间，坚持较长时间服用子仁激酶片，具有消除动脉回声斑作用，具有临床意义。
具体实施方式
实施例1
（一）制备子仁激酶
(1)先进行菌种培养，取从中国科学院微生物研究所购进的枯草芽孢杆菌1支，接种于营养肉汁琼脂培养基上，营养肉汁琼脂培养基主要由下述原料组成：蛋白胨10克，牛肉膏 3克，琼脂5克，氯化钠5克加无菌水至1000毫升，并调PH至7，上述原料配制成的培养基分为七支，按常规菌种培养方法在30-38℃条件下培养24-48 小时，然后合并所培养的菌种得到菌种培养液；
(2)取上述菌种培养液25毫升、28毫升、32毫升、36毫升50毫升分别加入35公斤子仁浆中搅拌均匀，在37℃的条件下发酵18-24小时，期间每4小时搅拌 一次，让子仁浆均匀发酵；
(3)上述发酵好的子仁浆置于5℃-8℃的条件下稳定后熟24-30小时，取出于32-38℃以下的温度干燥至含水量为7％以下即可。
经上述方法制备得到5批子仁激酶，经广西壮族自治区分析测试中心对五批子仁激酶进行检验，活性单位为2839U/g-4230U/g。
实施例2
（二）制备中药提取物
（1）配方：丹参3000克 山楂2000克 红花600克
三七1000克 天麻1000克 红景天2000克
远志2000克 瓜蒌壳2000克 回心草2000克 花旗参1000克；
（2）制备方法：取丹参、山楂、红花、红景天、远志、瓜蒌壳和回心草洗净、晾干，加入100千克的水浸泡1小时，加热提取2小时，过滤得滤液备用，残渣再加入100千克水，加热提取2小时，过滤取滤液，收集2次提取的滤液合并，减压浓缩，浓缩至80℃时检测相对密度为1.15，得到药物提取液10千克备用；
另取三七、天麻和花旗参，冼净，干燥，粉碎为200目细粉，得到3000克药物细粉备用；
将上述药物细粉加入上述药物提取液中混合均匀，按常规方法加入适量糊精制备成颗粒，干燥，使得每克颗粒剂含生药量为2.5克，即得中药提取物。
实施例3
制备中药提取物
（1）配方：丹参4000克 山楂3000克 红花2000克
三七1000克 1麻2000克 红景天3000克
远志3000克 瓜蒌壳3000克 回心草3000克 花旗参1000克；
（2）制备方法：取丹参、山楂、红花、红景天、远志、瓜蒌壳和回心草洗净、晾干，加入200千克的水浸泡1小时，加热提取2小时，过滤得滤液备用，残渣再加入100千克水，加热提取2小时，过滤取滤液，收集2次提取的滤液合并，减压浓缩，浓缩至80℃时检测相对密度为1.12，得到药物提取液20千克备用；
另取三七、天麻和花旗参，冼净，干燥，粉碎为200目细粉，得到3000克药物细粉备用；
将上述药物细粉加入上述药物提取液中混合均匀，按常规方法加入适量糊精制备成颗粒，干燥，使得每克颗粒剂含生药量为3克，即得中药提取物。
实施例4
制备子仁激酶片
配方：
子仁激酶 300克 红曲 200克 中药提取物 100克；
通过下述制备方法将上述原料制备成片剂：
取子仁激酶和红曲混合均匀，再加入中药提取物混合均匀，加入100克糊精混合均匀，先制备成颗料剂，再将颗料剂压制为片重是0.3克的子仁激酶片2330 片，每片含子仁激酶的量是0.128克。所述红曲是市售商品，由西安市陕西天行健生物化工技术有限公司购进。
实施例5
制备子仁激酶胶囊
配方：
子仁激酶 500克 红曲 400克 中药提取物 200克；
通过下述制备方法将上述原料制备成胶囊剂：
取子仁激酶和红曲提取物混合均匀，再加入中药提取物混合均匀，加入辅料羟甲基纤维素钠70克，先制备成颗料剂，再将颗料剂分装入内容物重是0.3克的胶囊即得到4000粒胶囊剂，每粒胶囊含子仁激酶的量是0.128克。
Claims (3)
1.一种具有降低血粘度的药物组合物，其特征在于所述药物组合物由下述重量份原料制备而成：
配方：
子仁激酶 3-5份 红曲 2-4份 中药提取物 1-2份；
通过下述制备方法将上述原料制备成片剂或胶囊剂：
取子仁激酶和红曲提取物混合均匀，再加入中药提取物混合均匀，根据制备片剂的常规工艺要求加入辅料，先制备成颗料剂，再将颗料剂压片即得到片剂，或将颗粒剂分装入胶囊即得到胶囊剂，所述片剂中每片含子仁激酶的量是0.126-0.128克，所述胶囊剂中每粒含子仁激酶的量是0.126-0.128克。
2.根据权利要求1所述的一种具有降低血粘度的药物组合物，其特征在于所述子仁激酶的制备方法是：取等量炒决明子和炒桃仁，烘干，粉碎为40-80目细粉，以1:1.2-1.7的重量比用水调成浆状,浸润20-30分钟后，隔水蒸30-40分钟，使蛋白变性得到子仁浆，于35公斤子仁浆中加入30-50毫升枯草芽胞杆菌培养液,搅拌均匀, 在35℃-40℃的条件下发酵18-24小时，期间每4小时搅拌 一次，让子仁浆均匀发酵,取发酵好的子仁浆置于5℃8℃的条件下稳定后熟24-30小时，取出于35℃-40℃以下的温度干燥至含水量为7％以下即得。
3.根据权利要求1所述的一种具有降低血粘度的药物组合物，其特征在于所述中药提取物的制备方法是：
配方：丹参3-4重量份 山楂2-3重量份 红花1-2重量份
三七1-2重量份 天麻1-2重量份 红景天2-3重量份
远志2-3重量份 瓜蒌壳2-3重量份 回心草2-3重量份
花旗参1-2重量份；
制备方法：取丹参、山楂、红花、红景天、远志、瓜蒌壳和回心草洗净、晾干，加入5-8倍量的水浸泡1小时，加热提取2小时，过滤得滤液备用，残渣按上述方法重复提取1次，收集2次提取的滤液，减压浓缩，浓缩至80℃时检测相对密度为1.12-1.15，得到药物提取液备用；
另取三七、天麻和花旗参，冼净，干燥，粉碎为200目细粉，得到药物细粉备用；
将上述药物细粉加入上述药物提取液中混合均匀，按常规方法加入适量辅料制备成颗粒，干燥，使得每克颗粒剂含生药量为2.5-3克，即得中药提取物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010176270.3A CN111281971A (zh) | 2020-03-13 | 2020-03-13 | 一种具有降低血粘度的药物组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010176270.3A CN111281971A (zh) | 2020-03-13 | 2020-03-13 | 一种具有降低血粘度的药物组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111281971A true CN111281971A (zh) | 2020-06-16 |
Family
ID=71020690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010176270.3A Pending CN111281971A (zh) | 2020-03-13 | 2020-03-13 | 一种具有降低血粘度的药物组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111281971A (zh) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102038745A (zh) * | 2009-10-18 | 2011-05-04 | 廖德宏 | 一种降血脂中药 |
| CN103103244A (zh) * | 2013-02-22 | 2013-05-15 | 北京市农林科学院 | 核桃降血压活性肽及其制备方法与应用 |
| CN103655697A (zh) * | 2012-09-26 | 2014-03-26 | 郑州御寿堂健康产业科技发展有限公司 | 一种降血脂的产品及其制备工艺 |
| CN105343520A (zh) * | 2015-11-29 | 2016-02-24 | 姜辉阳 | 一种治疗心脑血管疾病的中药组合物 |
| CN106616351A (zh) * | 2016-12-21 | 2017-05-10 | 安徽豆宝食品有限公司 | 一种降脂活血糙细粉及其制备方法 |
| CN108185410A (zh) * | 2017-12-13 | 2018-06-22 | 天津科技大学 | 一种抗肿瘤益生菌发酵功能性食品及其制备方法 |
| CN110201041A (zh) * | 2019-07-17 | 2019-09-06 | 四川省中药饮片有限责任公司 | 一种活血化瘀通脉降脂的组合物 |
-
2020
- 2020-03-13 CN CN202010176270.3A patent/CN111281971A/zh active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102038745A (zh) * | 2009-10-18 | 2011-05-04 | 廖德宏 | 一种降血脂中药 |
| CN103655697A (zh) * | 2012-09-26 | 2014-03-26 | 郑州御寿堂健康产业科技发展有限公司 | 一种降血脂的产品及其制备工艺 |
| CN103103244A (zh) * | 2013-02-22 | 2013-05-15 | 北京市农林科学院 | 核桃降血压活性肽及其制备方法与应用 |
| CN105343520A (zh) * | 2015-11-29 | 2016-02-24 | 姜辉阳 | 一种治疗心脑血管疾病的中药组合物 |
| CN106616351A (zh) * | 2016-12-21 | 2017-05-10 | 安徽豆宝食品有限公司 | 一种降脂活血糙细粉及其制备方法 |
| CN108185410A (zh) * | 2017-12-13 | 2018-06-22 | 天津科技大学 | 一种抗肿瘤益生菌发酵功能性食品及其制备方法 |
| CN110201041A (zh) * | 2019-07-17 | 2019-09-06 | 四川省中药饮片有限责任公司 | 一种活血化瘀通脉降脂的组合物 |
Non-Patent Citations (5)
| Title |
|---|
| 刘潇，等: "枯草芽孢杆菌和黑曲霉固态发酵制备核桃多肽的工艺条件优化", 《现代食品科技》 * |
| 医学教育网: "桃仁的现代研究", 《HTTPS://WWW.MED66.COM/ZHONGYAOSHI/HL1408142612.SHTML》 * |
| 自强不息在等你: "30个小偏方，救人无数，太珍贵了！快存手机上试试！", 《WWW.360DOC.COM/CONTENT/19/1129/21/9047527_876400144.SHTML》 * |
| 金玲，等: "决明子发酵前后5种蒽醌类成分变化研究", 《中国药房》 * |
| 马杰: "桃仁苦杏仁苷的提取及其抑菌活性研究", 《食品工业》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104826087A (zh) | 复合辣木多肽及其制备方法和应用 | |
| CN102362881A (zh) | 银杏洋参制剂的生产方法 | |
| CN101473943A (zh) | 一种改善记忆功能的保健食品及其制备方法 | |
| CN103301201B (zh) | 一种提高免疫力辅助抗肿瘤的中草药复方 | |
| CN105341893A (zh) | 一种辅助降血糖的组合物及应用 | |
| CN103349671A (zh) | 一种白藜芦醇螺旋藻组合物及其制剂和制法 | |
| CN112370516A (zh) | 一种具有活性成分的破壁灵芝孢子粉制品及其制备方法 | |
| CN104055935A (zh) | 一种协同提高免疫力的中药组合物 | |
| CN101683387B (zh) | 一种药物及其制备方法与应用 | |
| CN103932172B (zh) | 一种虫草保健品及其制备方法 | |
| CN100381164C (zh) | 一种治疗化疗、放疗、放射病的药物 | |
| CN110856530A (zh) | 一种桦树茸保健饮品 | |
| CN111281971A (zh) | 一种具有降低血粘度的药物组合物 | |
| CN108567914A (zh) | 一种具有改善睡眠作用的中药制剂及其制备方法和应用 | |
| CN104225425A (zh) | 一种提高免疫力、改善睡眠、预防心脑血管疾病的中药制剂及其制备方法 | |
| CN107812115A (zh) | 一种治疗糖尿病的中药组合物 | |
| CN114145374A (zh) | 一种黄芪玉须复合茶及其制备方法和应用 | |
| CN106928376A (zh) | 山茱萸多糖的分离方法及其应用 | |
| CN107536016B (zh) | 一种保护心脏和促进肝脏健康的营养食品 | |
| CN105596401A (zh) | 一种辅助降血糖的罗汉果制剂及其制备方法 | |
| CN101485716A (zh) | 一种治疗放射损伤药物及其制备方法 | |
| CN104256618A (zh) | 一种降血糖的食品、保健品或药物组合物 | |
| CN102526370A (zh) | 提高人体免疫功能的虫草制剂及其制备方法 | |
| CN114404487B (zh) | 黄根或其提取物在制备用于治疗胶质瘤的药物中的应用 | |
| CN107242570A (zh) | 一种提高免疫力抗疲劳的保健食品 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200616 |
|
| WD01 | Invention patent application deemed withdrawn after publication |